Robin Murphy
Researcher at the University of Auckland School of Pharmacy
Data updated
Papers
Trials
Research Footprint
Robin Murphy appears in 13 tracked papers (2021–2026), most studied alongside LSD, Psilocybin and Placebo, across Microdosing, Anxiety Disorders and Healthy Volunteers.
Most-cited paper: Trial of Psilocybin versus Escitalopram for Depression (1334 citations).
Frequent co-authors: Suresh Muthukumaraswamy, Rebecca Sumner and Ashleigh Murphy-Beiner.
Background & Research
Robin J. Murphy is a researcher associated with the University of Auckland’s School of Pharmacy. PubMed-indexed papers list her as a coauthor on studies of microdosed LSD, including a randomized controlled trial in healthy volunteers and a follow-up study on sleep duration after microdosing. She also appears as a coauthor on work discussing psychedelic therapy frameworks and personality change in a psilocybin versus escitalopram depression trial.
Key Impact
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Collaboration Network
24 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Robin Murphy is associated with.
University of Auckland
The University of Auckland hosts academic psychedelic research activity, including work led by Professor Suresh Muthukumaraswamy on LSD microdosing and related mental health applications.
View stakeholder →University of Wisconsin–Madison School of Pharmacy
The University of Wisconsin–Madison School of Pharmacy is the pharmacy school of the public research university UW–Madison, located in Madison, Wisconsin. It offers professional (PharmD), graduate and research programs in pharmaceutical sciences, clinical pharmacy, and related fields.
View stakeholder →